TP53 gene mutation can be detected in 50% to 80% of undifferentiated thyroid carcinoma and 7% to 25% in OCCs,[32–34] demonstrating its association with the dedifferentiation of thyroid cancer. The gene discussed is TP53; the disease is oculocerebrocutaneous syndrome.